49 results
8-K
EX-99.1
BAX
Baxter International Inc.
6 Jul 23
Regulation FD Disclosure
8:30am
actions undertaken by the United States or foreign governments; the outcome of pending or future litigation, including the opioid, ethylene oxide
8-K
EX-99.1
BAX
Baxter International Inc.
27 Apr 23
Baxter Reports First-quarter 2023 Results
7:18am
the opioid, ethylene oxide and Linet antitrust litigation or other claims; the impact of competitive products and pricing, including generic competition
8-K
EX-99.1
BAX
Baxter International Inc.
27 Oct 22
Baxter Reports Third-quarter 2022 Results
7:18am
in lifting the warning letter at the company’s Ahmedabad facility; the outcome of pending or future litigation, including the opioid litigation
8-K
EX-99.1
um39ai szoh7c
30 Sep 22
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-99.1
3y77h2mev3nr 822g85
28 Jul 22
Baxter Reports Second-quarter 2022 Results
7:19am
8-K
EX-99.1
73f7idoq7npndqmn w6
25 May 22
Baxter Highlights Business Strategies and Innovation
9:11am
424B3
agm8g1bsc8weg30
12 May 22
Prospectus supplement
8:58am
8-K
EX-99.1
hm9gf1fino tqptlit7d
28 Apr 22
Baxter Reports First-quarter 2022 Results
7:19am
8-K
EX-99.1
dbidcv
17 Feb 22
Baxter Reports Fourth-quarter and Full-year 2021 Results
7:18am
8-K
EX-99.1
drhk501jj0j04fucs
13 Dec 21
Creating ~$15 Billion Global Medtech Leader
4:46pm
8-K
fsacus8n66yo
13 Dec 21
Creating ~$15 Billion Global Medtech Leader
4:46pm
8-K
ax3chbs4r7o5ab
15 Nov 21
Regulation FD Disclosure
8:19am